College of Basic Medical Sciences

undefined

LU Liming

Immunoregulation Research Group

Tel: 63846590-776723

Email: lulunew2003@163.com

Research Field

  • Induction of immune tolerance in allogenic organs;

  • Mechanism and clinical research of immunotherapy;

  • Clinical applications and mechanism study of mesenchymal stem cells;

  • Investigation of Chinese Traditional Medicine drug Trichosanthin (Tk) and its derived peptides in immunomodulation.

Personal Introduction

  • Professor, PhD Supervisor

  • Principle Investigator of Immunomodulation Research Group

  • Executive-Editor-in-Chief of Journal of Current Immunology

  • Shanghai Pujiang Talent

  • Shanghai Shuguang Scholar

  • Shanghai Science and Technology Enlightened Star Talent Program

  • Backbone Teacher of Shanghai Municipal Education Commission

  • Outstanding Youth in Shanghai Health System

  • Morning Star Scholar of Jiaotong University

  • New Hundred Talents of Medical College

Education

  • 1994-1998 Xiamen University, B.S.

  • 1998-2001 Shanghai Jiao Tong University School of Medicine, M.S.

  • 2003-2006 Shanghai Jiao Tong University School of Medicine, Ph.D.

Career

  • 2001-2003 Leader, Shanghai Tissue Engineering Research and Development Center

  • 2006-2008 Lecturer, Shanghai Jiao Tong University School of Medicine

  • 2009-2014 Shanghai Jiao Tong University School of Medicine, Associate Researcher, M.S. Supervisor, RBL Supervisor

  • 2014-Present PI, Professor, PhD Supervisor, Shanghai Jiao Tong University School of Medicine, Executive Editor-in-Chief of Journal of Current Immunology

  • 2012-2020 Director of experimental center of Shanghai Chest hospital

  • 2013-2014   Senior Visiting Scholar, Cambridge University

  • 2018.03-07  Project evaluation expert in National natural science foundation of China

Social Service

  • Vice chairman of immune genetics committee of Shanghai society of immunology

  • National doctoral dissertation evaluation expert of degree center of ministry of education

  • Member of the Chinese society for immune-biotherapy

  • Executive-Editor-in-Chief of Current Immunology

  • Mentor of Research Basic Learning (RBL)program and Problem Basic Learning  Program (PBL)

  • National project evaluation expert

  • Key member of high level collaborative innovation team for pediatric liver transplantation of Jiaotong university medical school

Research Grants

Host Projects:

  • National Natural Science Foundation of China Grants(82071856), Application of Trichosanthin as an immunosynergist for group A meningitis vaccine,, Principal Investigator, 2021-2024

  • National Major Basic Science R & D Program, Ministry of Science and Technology. Reconstruction and regulation mechanism of the adaptive immune system post haploid genotype match transplantation, Principal Investigator, 2017-2021

  • National Natural Science Foundation of China Grants, Suppression of lung allo-transplantation chronic rejection by Trichosanthin-derived Peptide induced Treg, 81671579, Principal Investigator,2017-2020

  • National Natural Science Foundation of China Grants, The molecular immunology mechanism of CIITA regulating Th2 via NLR signal pathway, 31370904, Principal Investigator, 2014-2017

  • National Natural Science Foundation of China Grants, Comparative Study on Immunobiological Properties of Th9 Subset and IL-9+IL-10+T Cells induced by Trichosanthin-derived Peptide tetramer, 30972691, Principal Investigator, 2010-2012

  • National Natural Science Foundation of China Grants, Functional Knockout of Mouse MHC by transgene a CIITA mutant and the analysis of the underlying mechanisms, 30700766, Principal Investigator, 2008-2010

  • Shanghai Science and Technology Commission Experimental Animal Project,  Exploring the construction of a double humanized PDX model for lung cancer and the evaluation of drug treatment options for clinical patients, 18140903800, Principal Investigator, 2018-2021

  • Shanghai Municipal Bureau of Traditional Chinese Medicine Project, The role of histone demethylase LSD1 on the maintenance of CD8+ Treg profile induced by Trichosanthin, 2020JP009, Principal Investigator,2020-2022

  • Shanghai Science-Technology Foundation Key Program, Pharmacodynamics study of Trichosanthin active components in the regulation of Treg, 15401900500, Principal Investigator, 2015-2018

  • Shanghai Shuguang Scholar Program, Mechanism of treatment of OB using Trichosanthin-derived peptide, 16SG14, Principal Investigator, 2017-2019

  • Shanghai Pujiang Talent Program, Mechanism of using Trichosanthin-derived peptide in the treatment of Th1 dominant diseases, 15PJD021, Principal Investigator, 2015-2017

  • Shanghai Science and Technology Council Program, Translational research of lung cancer treatment using immune cells, 14DZ1931003, Principal Investigator, 2014-2017

Participating Projects:

  • National Major Basic Science R & D Program, Ministry of Science and Technology, Clinical study of human umbilical cord mesenchymal stem cells in the treatment of optic neuromyelitis optica spectrum disease, 2020YFA010045, 2021-2025

  • 973 Grant from the Ministry of Science and Technology of China, Study on Tissue stem cell stemness maintenance, control of differentiation and immune regulation, 2010CB945600

  • National Natural Science Foundation of China Grants, The significance of epigenetic control in Th1/Th2 differentiation and MHC transcriptional activation, 30530690

Publications

  • RIG-I acts as a tumor suppressor in melanoma via regulating the activation of the   MKK/p38MAPK signaling pathway. Hum Cell. Rui Guo, Shun-Yuan Lu, Jin-Xia Ma, Qian-Lan Wang, Lu Zhang, Ling-Yun Tang, Yan Shen, Chun-Ling Shen, Jin-Jin Wang, Li-Ming Lu, Zhu-GangWang, Hong-Xin Zhang:2022 Apr 13. doi: 10.1007/s13577-022-00698-1

  • Tumor-infiltrating PD-L1+ Neutrophils Induced by GM-CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis. Journal of Inflammation Research. Di Tang#, Duo Zhang#, Yu Heng, Xiao-ke Zhu, Han-qing Lin, Jian Zhou, Lei Tao*, and Li-ming Lu* 2022 Feb. 16;15:1079-1097

  • Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR- targeted therapy in lung cancer. Sci Transl Med 2021 Oct 6;13(614):eabg6428. Ke-Ren Zhang , Yu-Fei Zhang , Hui-Min Lei , Ya-Bin Tang , Chun-Shuang Ma , Qian-Ming Lv , Shi-Yi Wang , Li-Ming Lu , Ying Shen , Hong-Zhuan Chen , Liang Zhu.

  • Prognostic Impact of Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma Patients. Laryngoscope. 2020 Oct 27. doi: 10.1002/lary.29196. Duo Zhang; Di Tang; Yu Heng; Xiao-Ke Zhu; Liang Zhou; Lei Tao; Li-Ming Lu*

  • A systematic analysis identifies key regulators involved in cell proliferation and potential drugs for the treatment of human lung adenocarcinoma. Frontiers in Oncology-Thoracic Oncology.  2021 Sep 28;11:4-15. Kai Wang, Man Zhang, Jiao Wang, Jizhuang Luo, Pan Sun, Haizhen Jing, Rong Li, Changqing Pan, Li-Ming Lu*.

  • Dysregulation of DPP4-CXCL12 balance by TGF-β1/SMAD pathway promotes CXCR4+ inflammatory cell infiltration in keloid scars. Journal of Inflammation Research. 2021 Aug 26; 14:4169-4180. ZongAn Chen, Zhen Gao, LingLing Xia, XiaoQing Wang, Li-Ming Lu* XiaoLi Wu *..

  • BCL11A promotes the progression of laryngeal squamous cell carcinoma. Frontiers in Oncology. 2020 Mar 20;10:375. doi: 10.3389/fonc.2020.00375. Jian Zhou, Liang Zhou, Duo Zhang, Wei-Jing Tang, Di Tang, Xiao-Ling Shi, Yue Yang, Lin Zhou, Fei Liu, Yong Yu, Pentao Liu, Lei Tao, Li-Ming Lu*.

  • CXCL8high inflammatory B cells in the peripheral blood of patients with biliary atresia are involved in disease progression. Immunology & Cell Biology. 2020; 1–11. Zhang Yu; Zhou Lin; Gu Xiang; Feng Xuan; Ding Ping; Xia Qiang; Li-Ming Lu*

  • Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer. Anti-Cancer Drugs. 2020 August; 31(7):702-708. Zhang, Na; Sun, Pan; Jin, Haizhen; Yang, Yuqin; Zhao, Qingya; Zhou, Lin; Guo, Lili; Yang, Xiaohua; Li-Ming Lu*

  • Link Between CIITA rs3087456 Polymorphism and the Risk of Laryngeal Squamous Cell Carcinoma in a Chinese Population. Pathol Res Pract. 2020 Jan;216(1):152793. Yi Xue , Di Tang , Sheng-Jie Li , Jian Zhou , Chi-Yao Hsueh , Dan-Dan Zhao , Yu Heng , Lei Tao, Li-Ming Lu*

  • IL-33 promotes the progression of nonrheumatic aortic valve stenosis via inducing differential phenotypic transition in valvular interstitial cells. Journal of cardiology. 2019 Aug 12. HeYu-Bin; GuoJiang-Hong; WangChong; Zhu Dan; Lu Li-Ming*.

  • PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. Trends Mol Med.2020 Nov 13;S1471-4914(20)30266-5. Christopher D Nishimura, Marc C Pulanco, Wei Cui, Liming Lu, Xingxing Zang.

  • Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo. Exp Ther Med. 2019 Jan;17(1):739-747. Lin Ye, Yuqing Lou, Liming Lu* and Xiaohong Fan.

  • A Pathologic Complete Response to Neoadjuvant Chemotherapy and Immunotherapy Followed by Surgery in a Patient With NSCLC. Journal of Thoracic Oncology, 2019, 14(5): E104-E106.Ma, Xiao; Li, Bin; Li, Yuan; Lu, Liming; Chen, Haiquan

  • Correlation Between the NLRP3 Inflammasome and the Prognosis of Patients With LSCC. FRONTIERS IN ONCOLOGY , 2019 , Jul 2;9:588. Yi xue, Huai-Dong Du, Di Tang, Duo Zhang, Jian Zhou, Chang-Wen Zhai, Cun-Cun Yuan, Chi-Yao Hsueh, Sheng-Jie Li, Yu Heng, Lei Tao and Li-ming Lu*.

  • CXCL16/CXCR6 Is Involved in LPS-induced Acute Lung Injury via P38 Signaling. Cell Physiol Biochem. 2019; 00; 1-10. Guo-wei Tu ,Min-jie Ju, Yi-jun zheng, Guang-wei Hao,Guo-guang Ma, Jun-yi Hou, Xue-peng Zhang, Zhe Luo, Li-ming Lu*.

  • Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy. European Respiratory Journal. 2019 Mar 1;53(3). pii: 1801562. doi: 10.1183/13993003.01562-2018. Jun Lu, Hua Zhong, Tianqing Chu, Xueyan Zhang, Rong Li, Jiayuan Sun, Runbo Zhong, Yuqin Yang, Mohammad Shah Alam, Yuqing Lou, Jianlin Xu, Yanwei Zhang, Jun Wu, Xiaowei Li, Xiaodong Zhao, Kai Li, Liming Lu*, Baohui Han.

  • CXCL12 is involved in α-synuclein-triggered neuroinflammation of Parkinson’s disease. Journal of J Neuroinflammation. 2019;16(1):263. Yuanyuan Li, Mengyue Niu, Aonan Zhao, Wenyan Kang, Zhichun Chen, Ningdi Luo, Liche Zhou, Xiongwei Zhu, Liming Lu* and Jun Liu*.

  • Establishment of porcine and human expanded potential stem cells. Nature cell biology, 2019, 21(6): 687. Gao, Xuefei; Nowak-Imialek, Monika; Chen, Xi; Chen, Dongsheng; Herrmann, Doris; Pei, Duanqing; Zhang, Yi; Lu, Liming; Yang, Fengtang; Kimber, Susan J; Ahmed, Asif; Yeung, William Shu Biu; Teichmann, Sarah A; Niemann, Heiner; Liu, Pentao.

  • SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation. Nature communications, 2018, 9(1): 3157. Xiaoyan Yu, Yimin Lao, Xiao-Lu Teng, Song Li, Yan Zhou, Feixiang Wang, Xinwei Guo, Siyu Deng,  Yuzhou Chang, Xuefeng Wu, Zhiduo Liu, Lei Chen, Lming Lu, Jinke Cheng, Bin Li, Bing Su, Jin Jiang, Hua-Bing Li, Chuanxin Huang, Jing Yi & Qiang Zou .

  • Metabolic control of regulatory T cell stability and function by TRAF3IP3 at the lysosome. J Exp Med . 2018 Sep 3;215(9):2463-2476. doi: 10.1084/jem.20180397.  Xiaoyan Yu, XiaoLu Teng, Feixiang Wang, Yuhan Zheng, Guojun Qu, Yan Zhou, Zhilin Hu, Zhongqiu Wu, Yuzhou Chang, Lei Chen,HuaBing Li, Bing Su, Liming Lu*, Zhiduo Liu, ShaoCong Sun, and Qiang Zou.

  • Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy. Scientific Reports,2018,8(1):3917 Dongfang Tang, Ruyong Yao, Dandan Zhao, Lin Zhou, Yun Wu, Yang Yang, Yifeng Sun, Liming Lu, Wen Gao

  • The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer .JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22(8): 3847-3856.Tang, Dongfang; Zhao, Dandan; Wu, Yun; Yao, Ruyong; Zhou, Lin; Lu, Liming*; Gao, Wen*; Sun, Yifeng*

  • Peptede TK-PQ induces immunosuppression in skin allogeneic transplantation via increasing Foxp3+ Treg and impeding nuclear translocation of NF-κB. Molecular Immunology. 2018 Sep;101:597-607. doi: 10.1016/j.molimm. Yue Wang, Qing Li, Lin Zhou, Xueping Ding, Li-ming Lu*.

  • Obesity or Overweight, a Chronic Inflammatory Status in Male Reproductive System, Leads to Mice and Human Subfertility. Frontiers in Physiology, 2018, 8:1117. doi: 10.3389/fphys. Weimin Fan, Yali Xu, Yue Liu , Zhengqing Zhang , Liming Lu* and Zhide Ding.

  • Characterization of Memory T Lymphocytes in Keloid Disease. Br J Dermatol. 2018 Apr;178(4):940-950. doi: 10.1111/bjd.16173. ZongAn Chen*, Lin Zhou*, TaeHao Won, Zhen Gao, XiaoLi Wu, Li-ming Lu*.

  • Genetic polymorphisms and plasma levels of BCL11A contribute to the development of laryngeal squamous cell carcinoma. PloS one, 2017 Feb 22;12(2):e0171116. Zhou, J., Yang, Y., Zhang, D., Zhou, L., Tao, L., & Lu L*.

  • 28.Regulatory T Cells may Play an Protection Role in Lung Injury after Operation in Rheumatic Heart Disease. Journal of Thoracic Disease, 2018 Jun;10(6):3196-3205. doi: 10.21037/jtd.2018.05.71. Xiao-yang Zhang, Lin Zhou, Zhen Guo, Ye Kong, Wei Zhang, Li-ming Lu*,Xin Li*.

  • Establishment of mouse expanded potential stem cells.[J] .Nature, 2017, 550(7676): 393-397. Yang Jian,Ryan David J,Wang Wei, Jason Cheuk-Ho Tsang, Guocheng Lan, Hideki Masaki, Xuefei Gao, Liliana Antunes, Yong Yu,  Zhexin Zhu, Juexuan Wang, Aleksandra A. Kolodziejczyk, Lia S. Campos, Patrick P. L. Tam, Hiromitsu Nakauchi,  Xiangang Zou, Liming Lu & Pentao Liu*.

  • Role of T helper 17 cytokines in the tumour immune inflammation response of patients with laryngeal squamous cell carcinoma.[J] .Oncol Lett, 2017, 14(1): 561-568. Tang Wei-Jing,Tao Lei, Li-ming Lu* .

  • Association of the recurrence of vocal leukoplakia with MDM2-309 variants over a 2-year period: a prospective study. Acta Otolaryngol, 2016.136, 95-9. Zhou, J, Y. Yang, D. Zhang, L. Zhou, F. Liu, L. Tao, Lu L*.

  • Objective measurement and significance of PD-L1, B7-H3, B7-H4 and TILs in small cell lung cancer (SCLC). Journal of Clinical Oncology, 2016, 34: 8566-8566. Kurt Alex, Schalper; Daniel E., Carvajal-Hausdorf; Joseph Francis, McLaughlin; Mehmet, Jie, Zhang, Liming Lu, Baohui, Han, Hui, Lu.

  • Association of the recurrence and canceration rate of vocal leukoplakia with interleukin-10 promoter variants over a 2-year period. Acta Otolaryngol, 2016. 136, 1147-1153. ZhouJ, D.Zhang, L. Zhou, Y. Yang, F. Liu, L. Tao, Lu L*

  • New insights into myeloid-derived suppressor cells and their roles in feto-maternal immune cross-talk. J Reprod Immunol. 2015 Nov 10;113:35-41. doi: 10.1016/j.jri.2015.11.001. Zhao AM, Xu HJ, Kang XM, Zhao AM, Lu. L* ..

  • The ratio of CD4/CD8 T-cells in human papillomavirus-positive laryngeal squamous cell carcinoma accounts for improved outcome. Acta Otolaryngol, 2016.136, 826-33. Zhang, D, W. J. Tang, D. Tang, J. Zhou, L. Chou, L. Tao &Lu L*

  • Neutrophil infiltration mediated by CXCL5 accumulation in the laryngeal squamous cell carcinoma microenvironment: A mechanism by which tumour cells escape immune surveillance. Clinical Immunology, 2017, 175: 34-40. Zhang D, Zhou J, Tang D, Lei Tao, Lu L*.

  • Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its developmental pathway. Nature. 2016 Sep; 539(7627). Yu, Y, Tsang, C-H. J, Wang, C, Simon Clare, Juexuan Wang,Xi Chen, CordeliaBrandt, Leanne Kane, Lia S. Campos, Lu Lu*, Gabrielle T. Belz, Andrew N. J. McKenzie,Sarah A.Teichmann, Gordon Dougan& Pentao.

  • Association of the microsatellite (GT)n repeat polymorphisms of the HO-1 gene promoter and corresponding serum levels with the risk of laryngeal squamous cell carcinoma. Acta Otolaryngol, 2016. 136, 806-11. Tang, D, W. J. Tang, X. L. Shi, W. P. Li, H. Zhou, Lu L*, L. Tao.

  • Low concentration of Trichosanthin induces apoptosis and cell cycle arrest through JNK/MAPK activation. Molecular Medicine Report. 2015 Jan;11(1):349-56. doi: 10.3892/mmr. Zhang D, Chen B, Zhou J, Zhou L, Li Q, Liu F, Chou KY, Tao L, Lu L*.

  • The transcription factor Bcl11b is specifically expressed in group 2 innate lymphoid cells and is essential for their development. The Journal of experimental medicine 2015; 212:865-74. Yu Y, Wang C, Clare S, Wang J, Lee SC, Brandt C, Burke S1, Lu L*, He D, Jenkins NA, Copeland NG, Dougan G, Liu P..

  • Signalling Through Retinoic Acid Receptors is Required for Reprogramming of Both Mouse Embryonic Fibroblast Cells and Epiblast Stem Cells to Induced Pluripotent Stem Cells. Stem Cells. 2015 May 33(5):1390-404. doi: 10.1002/stem.1926. Yang J, Wang W, Ooi J, Campos LS, Lu L*, Liu P

  • A peptide tetramer Tk-tPN induces tolerance of cardiac allografting by conversion of type 1 to type 2 immune responses via the Toll‐like receptor 2 signal‐promoted activation of the MCP1 gene. Immunology, 2016, 147(3): 355-366. Li Z, Yang N, Zhou L, Lu L*, Chou KY.

  • Single-cell transcriptomic reconstruction reveals cell cycle and multi-lineage differentiation defects in Bcl11a-deficient hematopoietic stem cells. Genome Biol. 2015 Sep 21;16(1):178. doi:10.1186/s13059-015-0739-5. Tsang JC, Yu Y, Burke S, Buettner F, Wang C, Kolodziejczyk , Teichmann SA, Lu L*, Liu P,

  • Significance of MDM2-309 polymorphisms and induced c orresponding plasma MDM2 levels in susceptibility to laryngeal squamous cell carcinoma.DNA Cell Biol. 2014 Feb;33(2):88-94. Zhou J, Liu F, Zhang D, Chen B, Li Q, Zhou L, Lu L*, Tao L.

  • Association of interleukin 10 promoter polymorphisms and corresponding plasma levels with susceptibility to laryngeal squamous cell carcinoma ONCOLOGY LETTERS 2014,7:1721-1727. Jian Zhou, Duo Zhang, Bin Chen, Qing Li, Lin Zhou, Fei Liu, Kuang-Yen Chou, Lei Tao, Lu L*.

  • A Trichosanthin-derived peptide suppresses type 1 immune responses by TLR2-dependent activation of CD8+CD28−Tregs Clinic immunology (2013), 153, 277–287. Neng Yang, Zuoqing Li, Zhijun Jiao, Peng Gu, Yun Zhou, Lu.L*, Kuang-Yen Chou

  • Genetic polymorphism and plasma levels of interleukin-22 contribute to the development of nonsmall lung cancer. DNA and CellBiology. 2014 Oct;33(10):705-14. doi: 10.1089/dna. F. Liu, X. Pan, L. Zhou, B. Chen, J. Shi, W. Gao and Lu. L*.

  • Cellular reprogramming by transcription factor engineering. Current Opinion in Genetics & Development 2014, 28:1–9. Tsang JC, Xuefei Gao, Lu. L*, Pentao Liu

  • Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Research, 2014 doi: 10.1093/nar/gku836. Xuefei Gao, Jason C.H. Tsang, Fortis Gaba, Donghai Wu, Lu L*, Pentao Liu

  • High CCR6/CCR7 expression and Foxp3+ Treg cell number are positively related to the progression of laryngeal squamous cell carcinoma. ONCOLOGY REPORTS 2013 30: 1380-1390. Bin Chen, Duo Zhang, Jian Zhou, Qing Li, Lin Zhou, Shi-Min Li, Li Zhu, Kuang-Yen Chou, Liang Zhou, Lei Tao, Lu L*,

  • Mutated MHC class II transactivator upregulates IL-33-dependent differentiation of Th2 subset through Nod2 binding for NLR signaling initiation. Journal of Biological Chemistry, 2012 Mar 23;287(13) :9972-9981. Yang ZQ, Yang N, Zhou Y, Xin LJ, Lu L*, Chou KY.

  • Con A-binding protein Zn-α2-glycoprotein on human sperm membrane is related to acrosome reaction and sperm fertility. International Journal of Andrology. 2012 Apr;35(2):145-157. Liu Y, Qu F, Cao X, Chen G, Guo Q, Ying X, Guo W, Lu L*, Ding Z.

  • Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. Journal ofLeukocyte Biology , 2011 Jul, 90 (1):77-86. Ding Q, Lu L, Xiaorong Zhou, Zhou Y, Chou KY. Co-first author

  • Phenotypic alterations of dendritic cells are involved in suppressive activity of trichosanthin-induced CD8+CD28- regulatory T cells. Journal of Immunology. 2010 Jul 1: 185(1):79-88. Wang B, Jiao Z, Shao X, Lu L, Yang N, Zhou X, Xin L, Zhou Y, Chou KY.

  • High level expression of B7H1 molecules by keratinocytes suppresses xeno- and allo- eactions by inducing type I regulatory T cells TransplantImmunology, 2009, 21: 192-197. Zhou XR, Zhou Y, Ding Q, Lu L, Yang N, Chou KY.

  • Up-regulation of IL-10 expression in dendritic cells is involved in Trichosanthin-induced immuno- suppression. Immunol Let 2007, 74-81. Zhou XR, Yang N, Lu L, Ding Q, Jiao ZJ, Zhou Y, Chou KY.

  • MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation. Immunol, 2007,122,476-485. Xiaorong Zhou,YangJiang, Lu L, Qing Ding,Kuang-Yen Chou.

  • Improvement of clinical medical students' comprehensive quality by the undergraduate innovative experimentation program; a teaching exploration. Clin Med Educ. Vol 3. No3,4. June 2016. Jinwen Hu, Xiaoqian Yang, Jun Na, Liming Lu.

Textbook compilation

  • 《Popular Science Books on Human Health and Immunization》,People's Medical Publishing House,associate editor

  • 《Principles of Immunology》,science press,editorial board member

  • 《Medical Immunology》,Tsinghua University Press,editorial board member

  • 《Medical immunology and immunological examination》,science press,editorial board member

  • 《Oral clinical immunology》,People's Medical Publishing House,editorial board member

  • 《Immunobiology》,science press,associate editor

Patent

  • Construction and application of a Chinese lung adenocarcinoma cell line (Patent Number or Application Number: ZL 201710426801.8).

  • PHOP Application for treating lung cancer (Patent Number or Application Number: ZL 201710373254.1).

  • Construction and application of a Chinese esophageal squamous carcinoma cell line (Patent Number or Application Number: 202010558292.6).

  • Construction and application of a Chinese lung squamous carcinoma cell line (Patent Number or Application Number: 202010547005.1).

  • Application of Trichosanthin in enhancing vaccine specific antibodies (Patent Number or Application Number: ZL201610049358.2).

  • Application and induction of a new CD8+ regulatory T cell in immune regulation (Patent Number or Application Number: 202010965416.2).

  • Screen of immunosuppressive effective epitope of Trichosanthin (Patent Number or Application Number: ZL201210390572.6).

  • Trichosanthin derived peptide and its application (Patent Number or Application Number: ZL200710173408.9).